| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
CLINICAL REVIEW |
Department of Neurosciences, Ospedale Maggiore Policlinico, IRCCS (M.L.), 20122 Milan, Italy; and Department of Neurological Surgery, Department of Internal Medicine-Endocrinology, University of Virginia Health Sciences Center (M.L.V., E.R.L.), Charlottesville, Virginia 22908-0212
Address all correspondence and requests for reprints to: Dr. Edward R. Laws, Neurosurgery, Box 800212, University of Virginia Health System, Charlottesville, Virginia 22908-0212. E-mail: el5g{at}virginia.edu.
| Abstract |
|---|
|
|
|---|
Evidence Acquisition: We evaluated a strategy of immediate reoperation in surgical failures judged by plasma cortisol levels that did not fall to 2 µg/dl or less within 72 h of surgery. Of 215 patients with presumed ACTH microadenomas, treated between 1993 and 2004, 12 met inclusion criteria and had prompt (within 15 d) reoperation for residual or missed ACTH microadenoma. These 12 patients represent 28% of those who did not have evidence of postoperative adrenal insufficiency.
Evidence Synthesis: Based on an outcome measure of sustained subnormal or normal plasma cortisol levels, eight of 12 patients (67%) achieved remission from the two operations. Adjunctive therapies (radiotherapy, gamma knife radiosurgery, and adrenalectomy) led to remission in another three patients. It is recognized that this outcome required either total hypophysectomy (one patient) or postoperative hypopituitarism (all patients in remission).
Conclusion: Magnetic resonance imaging was not usually helpful in determining therapeutic strategies; however, inferior petrosal sinus sampling was critical in providing confidence that the disease was of pituitary origin. A treatment algorithm is recommended, based on this study.
| Introduction |
|---|
|
|
|---|
At present, the therapy of choice for Cushings disease is selective transsphenoidal resection of an ACTH-secreting microadenoma, with reported rates of postoperative remission varying from 7085%, a mortality rate of less than 1%, and morbidity of approximately 1.8% in major published series (1, 2, 3, 4, 5, 6, 7, 8). Subnormal or undetectable levels of serum cortisol in the immediate postoperative period have been suggested as predictive of long-term remission (9, 10, 11, 12, 13, 14, 15). In cases of surgical failure, repeat exploration of the sella represents a treatment option that has been advocated by Hardy, Zervas, Trainer and colleagues, Oldfield and colleagues, and others (10, 16, 17, 18, 19). Repeat surgical treatment several days after the first transsphenoidal operation allows the surgeon to reexplore the sella with minimal additional trauma and no major concern about altered surgical anatomy.
Few data are available from the literature on the effect of repeat transsphenoidal surgery for persistent Cushings disease (10, 16, 18, 19). In particular, only two studies have focused on the results and complications of this procedure when performed within a short interval of time after the first operative procedure (10, 19).
The aim of this study was to determine the safety and the potential efficacy of redo transsphenoidal surgery within 15 d of the first such operation in patients with persistent postoperative hypercortisolism
| Patients and Methods |
|---|
|
|
|---|
The major symptoms and their frequency were typical (6) and reflected the severity of disease in this subset of Cushings disease patients; the average duration of symptoms was 40.2 months (range, 384 months).
The diagnosis of Cushings disease was based upon currently accepted laboratory criteria (20). The endocrinological tests were performed both at the neuroendocrine unit of the University of Virginia and at other institutions. In the latter case the results were confirmed by endocrinologists in our Pituitary/Neuroendocrine Center.
The diagnostic protocol included a magnetic resonance imaging (MRI) study of the sellar region, which was performed in all cases before surgery. The contrast-enhanced MRI scans (pituitary protocol) were examined by the reporting radiologist and the operating neurosurgeon. They were defined as negative when a normal gland and a normal sellar region were present, equivocal when it was possible to recognize subtle changes suggestive, but not diagnostic, of adenoma, and positive when a tumor was identified.
The indication for inferior petrosal sinus sampling (IPSS) was related to the results of the endocrinological tests and the MRI. Eleven patients underwent IPSS preoperatively. This study was considered confirmatory of pituitary Cushings disease when the basal central to peripheral ACTH ratio was 2 or more or the CRH-stimulated central to peripheral ACTH ratio was 3 or more. The test was considered positive for lateralization when the side to side ACTH ratio was greater than 1.4 (21, 22).
The patients had unremarkable past medical histories, except for one who had undergone transsphenoidal surgery elsewhere 2 yr before admission to our institution (she had developed recurrent Cushings disease after 1 yr of clinical remission). Two patients had had previous thyroid surgery for Graves disease and goiter, respectively.
A single surgeon performed each microsurgical transsphenoidal operation via the endonasal [with the hemitransfixion or the pushover technique as previously described (23)] or sublabial route. When appropriate, endoscopic assistance was also used. Perioperative corticosteroid therapy was not administered. Our standard postoperative assessment after both the initial and second procedures consisted of the measurement of serum cortisol every 6 h for at least 3 d (14) or until serum cortisol was 2 µg/dl or less.
Patients were defined as being in remission when they developed clinical symptoms and laboratory evidence of adrenal insufficiency (serum cortisol,
2 µg/dl). The level of postoperative serum cortisol for definition of remission was 2 µg/dl or less.
The second transsphenoidal operation was performed within 15 d of the first procedure; the median interval between the two procedures was 5.08 d (range, 314 d). Serum cortisol was again measured every 6 h after surgery to assess the outcome. If the serum cortisol declined to 2 µg/dl or less, glucocorticoid replacement therapy was instituted immediately. The patients were followed regularly to assess adrenal function and clinical symptoms.
Of the 215 patients treated by initial transsphenoidal surgery, a total of 43 (20%) failed to achieve postoperative remission. Twelve of these patients had immediate reoperation. Among the others, five had undergone total hypophysectomy and did not have obvious ectopic parasellar pituitary tumor on MRI; they were not offered another operation. Seven were treated with radiation therapy, all but one with the gamma knife; four of these had locally invasive tumors. Six had not had IPSS and were followed. Thirteen patients either refused repeat surgery or were not offered another procedure, usually because they had a decrease toward normal serum cortisol levels. Desire for fertility and concern about full pituitary replacement therapy were also factors considered. Of the 32 patients who were not treated by immediate reexploration, none was later operated upon transsphenoidally.
| Results |
|---|
|
|
|---|
|
Complications of the initial transsphenoidal operation consisted of an alar tear in one case. Two patients had intraoperative cerebrospinal fluid (CSF) leaks successfully repaired using an abdominal fat graft.
In all cases the gross surgical findings were thought by the surgeon to be consistent with the presence of pathological tissue compatible with a microadenoma (size range, 28 mm). The initial pathology reports, however, were positive for ACTH adenoma in two cases and negative in 10 (Table 2
).
|
The second operation was performed via the endonasal route in 10 cases (two cases by the hemitransfixion submucosal method and eight by the septal pushover technique). A sublabial approach was chosen in two cases. In 10 cases a total hypophysectomy was performed, and in two cases a subtotal hypophysectomy was completed (Table 3
).
|
At follow-up, eight of the 12 patients (67%) were in remission after the two transsphenoidal operations; three other patients achieved remission after subsequent treatment (one patient underwent conventional radiotherapy of the sellar region, one bilateral adrenalectomy, and one gamma knife radiosurgery, followed by bilateral adrenalectomy). These three patients received medical therapy with ketoconazole, but it was discontinued in two patients because of liver toxicity and in one patient who failed to achieve a significant reduction of 24-h urinary free cortisol. The remaining patient, who had severe Cushings disease, died of heart failure before adjunctive therapy could be given. All 11 surviving patients are receiving appropriate hormonal replacement therapy.
| Discussion |
|---|
|
|
|---|
In patients who are not cured by surgery, four therapeutic options remain: repeat transsphenoidal operation, medical therapy, radiation therapy (conventional or radiosurgery), and bilateral adrenalectomy. The optimum treatment or sequence of different treatments has not yet been established. Because of the serious effects of Cushings disease, hypercortisolism must be treated as promptly and effectively as possible with the fewest adverse effects.
The efficacy and toxicity of medical and radiation therapy have been assessed previously as well as those of repeat reexploration of the sella (10, 18, 19). The role of immediate reoperation (within 15 d of the first operation) has rarely been investigated. Previous studies include those by Trainer et al. (10), who studied 10 patients with repeat surgery within 10 d, with a 70% remission rate. Ram and colleagues (19) reported on 17 patients who had a second operation 746 d after the first, with a 53% remission rate. The rationale of immediate reoperative transsphenoidal surgery is to remove the presumed residual accessible tumor or gland without the disadvantages (altered anatomy and scar tissue) of delayed surgery. This strategy, when successful, also limits the consequences of progressive Cushings disease. The presence of a positive IPSS test provides the surgeon with a significantly enhanced level of confidence when considering a secondary operative procedure.
After the two transsphenoidal operations, eight of our 12 patients (67%) are alive and in remission following surgical management alone. Three additional patients achieved remission after combined therapy.
Every reported series of transsphenoidal surgery for presumed ACTH-secreting microadenomas includes some 1530% of patients in whom the histopathology is negative for tumor. This occurs even in patients with positive IPSS, and a significant proportion of these patients may achieve postoperative remission of Cushings disease. In Rams report of Oldfields series (19), 11 of the 17 patients had no tumor found at the second procedure, and six of the 11 achieved remission. In our series, eight of the 12 patients had no tumor found at the second operation, and five had surgical remissions. This phenomenon is often explained by the loss of the critical pathological material in the operative suction apparatus or in transport or handling in the pathology laboratory. It remains a vexing problem in the analysis of outcome.
In our patients the surgical complications consisted of one case of pulmonary embolism due to deep venous thrombosis, one urinary tract infection, a superficial abdominal (fat graft) wound infection, and one patient with suspected transient meningitis and an alar tear. An intraoperative CSF leak occurred in two patients during the first operation and in 10 patients during the immediate redo operation. There were no cases of persistent or delayed postoperative CSF leak. Moreover, no cases of operative mortality (30 d) or of classical major morbidity (vascular injury/occlusion, sellar abscess, complicated meningitis, sellar pneumatocele, cranial nerve palsy, visual loss, or CSF rhinorrhea) occurred.
This study highlights a number of different considerations. First, an interesting point arises from the MRI data. A large number of patients had nondiagnostic studies (11 of 12 cases). This finding partially explains the high number of IPSS procedures performed (11 of 12). Considering the reluctance of a surgeon to operate on a patient with an equivocal or negative MRI scan, a positive IPSS study is without any doubt a powerful factor, allowing the surgeon to feel more confident in recommending an operation.
It is generally true in neurosurgery and certainly true for transsphenoidal surgery that complication rates are higher with reoperations, and outcomes are generally less favorable than after the initial operation (26, 27). Although the small number of patients can be considered a limitation of this study, the balance between positive results and surgical complications suggests that immediate reoperative transsphenoidal surgery for pituitary Cushings should be considered a safe and effective therapeutic strategy.
The management of patients with Cushings disease who fail to achieve postoperative remission is difficult, poorly defined, and often discouraging. Accordingly, a therapeutic algorithm for the management of Cushings disease incorporating immediate reoperative transsphenoidal surgery in this process has been developed (Fig 1
). This algorithm reflects our experience and our outcome data.
|
It is important to note that successful management of this relatively uncommon, but often devastating, disease is most likely to occur in collaborative centers where experience in diagnosis, surgery, and adjunctive therapy is available.
| Acknowledgments |
|---|
| Footnotes |
|---|
Abbreviations: CSF, Cerebrospinal fluid; IPSS, inferior petrosal sinus sampling; MRI, magnetic resonance imaging.
Received December 13, 2004.
Accepted June 6, 2005.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
C. G. Patil, D. M. Prevedello, S. P. Lad, M. L. Vance, M. O. Thorner, L. Katznelson, and E. R. Laws Jr. Late Recurrences of Cushing's Disease after Initial Successful Transsphenoidal Surgery J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 358 - 362. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Pouratian, D. M. Prevedello, J. Jagannathan, M. B. Lopes, M. L. Vance, and E. R. Laws Jr. Outcomes and Management of Patients with Cushing's Disease without Pathological Confirmation of Tumor Resection after Transsphenoidal Surgery J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3383 - 3388. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Findling and H. Raff Cushing's Syndrome: Important Issues in Diagnosis and Management J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3746 - 3753. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |